This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of solicited local and systemic adverse reactions
Timeframe: 7 days after each injection
To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of unsolicited adverse events
Timeframe: 28 days after each injection
To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of medically-attended adverse events (MAAEs
Timeframe: 30 weeks after first injection
To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of adverse events of special interest (AESI)
Timeframe: 30 weeks after first injection
To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of serious adverse events (SAE)
Timeframe: 30 weeks after first injection